Archived News Releases

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current news releases on nida.nih.gov.

Nasal spray naloxone one step closer to public availability

 |  The National Institute on Drug Abuse (NIDA) is pleased to announce that Adapt Pharma Limited, a partner of Lightlake Therapeutics Inc., has commenced a rolling submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for a nasal spray formulation of naloxone, a drug designed to prevent opioid overdose deaths.

Recreational marijuana use associated with increased impulsivity and hostility in daily life

 |  In a recent 14-day study using a smartphone-based EMA, recreational marijuana users (average use of 4.5 days over the past 30 days) who also drank alcohol at least once per week answered questions each day regarding their alcohol consumption, marijuana use, and number of cigarettes or cigars smoked. Participants also answered questions to assess hostility following any interaction with another person that lasted longer than five minutes. In addition, end-of-day surveys were completed to measure impulsivity.

NIDA researchers discover further complexity in brain reward circuitry

 |  NIDA scientists have identified new complexities within the brain’s reward circuitry that involves two major chemicals involved in drug addiction -- dopamine and glutamate. Researchers used rodent models to better understand a specific brain circuit where dopamine and glutamate are both released from the same brain cells.

The science behind designer drugs

 |  “Designer drugs,” such as bath salts (synthetic cathinones) and spice (synthetic cannabinoids) are manufactured to chemically resemble illicit drugs but can often be purchased legally because manufacturers continually modify their chemical structures in order to circumvent drug laws.

Genetics influence response to prevention intervention

 |  A new NIDA-funded study examined whether an individual’s collective gene-based sensitivity to the reinforcing aspects of nicotine (or his/her polygenic score) had an impact on how much he or she benefited from an elementary-school-based prevention intervention, as assessed by age of smoking initiation.

New CME/CE course addresses substance use

 |  Announcement A new continuing medical education/continuing education course (CME/CE), Talking to Patients About Health Risk Behaviors, adds to a growing body of tools available through the National Institute on Drug...